Effect of Huoxiang Zhengqi Pill on Early Neurological Deterioration in Patients with Acute Ischemic Stroke Undergoing Recanalization Therapy and Predictive Effect of Essen Score

Table 1

Comparison of variables between all patients with and without END.

Variable	All (n = 155)	Unadjusted OR	95% CI	value
Demographics
Age, mean (SD), years	63 (11)	1.045	1.006–1.085	0.024
Female, n (%)	44 (28.4)	0.925	0.355–2.407	0.873
BMI, Median (IQR)	23.7 (21.5–25.4)	1.043	0.902–1.206	0.568
Clinical characteristics
Systolic blood pressure Median (IQR), mm Hg	142 (130–158)	0.991	0.971–1.012	0.409
Diastolic blood pressure, Median (IQR), mm Hg	85 (76–92)	0.990	0.955–1.027	0.584
Sleeping well, n (%)	143 (92.3)	0.755	0.175–3.255	0.706
Dysphagia, n (%)	43 (27.7)	1.536	0.513–4.594	0.443
Baseline NIHSS score, median (IQR)	6 (2–11)	1.063	0.985–1.147	0.116
Essen score classification, n (%)
0–2	94 (60.6)	0.162	0.054–0.485	0.001
≥3	61 (39.4)	Reference
Cerebral infarction site, n (%)
Anterior circulation	111 (71.6)	0.925	0.355–2.407	0.873
Posterior circulation	44 (28.4)	Reference
Medical history
Smoking, n (%)	70 (45.2)	0.654	0.261–1.639	0.365
Drinking, n (%)	41 (26.5)	0.309	0.072–1.332	0.115
Hypertension, n (%)	98 (63.2)	2.327	0.778–6.959	0.131
Diabetes, n (%)	51 (32.9)	0.874	0.336–2.274	0.782
Dyslipidemia, n (%)	98 (63.2)	0.711	0.295–1.715	0.448
Atrial fibrillation, n (%)	27 (17.4)	1.185	0.396–3.545	0.761
Lab results
Uric acid, umol/L, mean (SD)	376.1 (115.0)	1.000	0.997–1.005	0.654
HDL, mmol/L, median (IQR)	1.0 (0.8–1.1)	3.333	0.833–13.334	0.089
TC, mmol/L, median (IQR)	4.7 (3.9–5.3)	0.933	0.656–1.327	0.699
TG, mmol/L, median (IQR)	1.7 (1.1–2.2)	0.937	0.560–1.568	0.804
LDL, mmol/L, median (IQR)	2.9 (2.1–3.3)	0.749	0.484–1.160	0.194
Glycated hemoglobin, %, median (IQR)	6.0 (5.7–6.5)	1.145	0.894–1.466	0.285
D-dimer, mg/L, median (IQR)	0.5 (0.3–1.4)	1.021	0.891–1.169	0.767
Fibrinogen, g/L, median (IQR)	3.6 (3.0–4.2)	1.008	0.854–1.189	0.926
FT3, Median (IQR), pmol/ml	4.3 (4.0–4.5)	0.497	0.172–1.433	0.196
TSH, Median (IQR), nmol/ml	1.8 (0.9–2.1)	0.751	0.465–1.211	0.240
FT4, Median (IQR), pmol/ml	15.2 (14.5–16.1)	0.907	0.716–1.149	0.419
Treatment procedures
Anticoagulant, n (%)	44 (28.4)	2.064	0.855–4.981	0.107
Antiplatelet, n (%)	139 (89.7)			0.228
Statin use, n (%)	148 (95.5)			0.596
Antihypertensive drugs, n (%)	87 (56.1)	1.452	0.579–3.638	0.427
Huoxiang Zhengqi Pill treatment, n (%)	77 (49.7)	0.253	0.085–0.757	0.014

Fisher’s exact test